City of Hope tests osteoporosis drug for type 1 diabetes

City of Hope, a major cancer and diabetes research center in the United States, is beginning a new clinical trial. This study will test an osteoporosis medication known as denosumab to see if it can help people with early type 1 diabetes. Denosumab is already approved by the FDA for treating osteoporosis and bone tumors. The trial will explore if it can protect and regenerate beta cells. These cells are responsible for producing insulin, which helps regulate blood sugar levels. In early type 1 diabetes, some beta cells can still function, even though the immune system is damaging them. This phase 1/2 trial is randomized, double-blind, and multicenter. It aims to find out if denosumab can improve beta cell function and help control blood sugar in patients who still produce some insulin. The researchers believe this could slow the progression of type 1 diabetes and potentially help other diabetes patients as well. Dr. Fouad R. Kandeel, who is co-leading the trial, is optimistic about this unique use of an existing medication. The trial is primarily funded by Breakthrough T1D and The Wanek Family Project for Type 1 Diabetes at City of Hope. Patients are being recruited in the Los Angeles area, as well as at the University of Alabama at Birmingham and Indiana University. Eligible participants must be adults aged 18 to 50, diagnosed with early type 1 diabetes within the last five years, and have some remaining beta cell function. The trial will involve 30 participants receiving the denosumab treatment and 15 receiving a placebo. Those taking denosumab will receive injections every three months for a total of four doses. Researchers will monitor participants for 12 months, looking for side effects and changes in their blood sugar control and beta cell function.